I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic's (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug that might be one part of a solution to the […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
